• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

P蛋白中YMDD基序之外的突变也可导致鸭乙肝病毒对拉米夫定耐药。

Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.

作者信息

He Jin-Yang, Zhu Yu-Tong, Yang Rui-Yi, Feng Li-Ling, Guo Xing-Bo, Zhang Feng-Xue, Chen Hong-Shan

机构信息

Tropical Medicine Institute of Guangzhou University of Traditional Chinese Medicine, Guangzhou 510405, Guangdong Province, China.

出版信息

World J Gastroenterol. 2005 Jul 21;11(27):4261-7. doi: 10.3748/wjg.v11.i27.4261.

DOI:10.3748/wjg.v11.i27.4261
PMID:16015703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4615456/
Abstract

AIM

To observe the Lamivudine resistance character of a DHBV strain in vitro and in vivo, and to analyze if the Lamivudine resistance character is caused by gene mutation or by abnormity of the Lamivudine metabolism.

METHODS

Congenitally DHBV-negative Guangdong brown ducks and duck embryo liver cells were respectively taken as animal and cell model. The Lamivudine-susceptive DHBV and Lamivudine-resistant DHBV (LRDHBV) were infected and Lamivudine was administrated according to the divided groups. The changes of DHBV quantity in the animal and cell model were tested. Three Lamivudine-resistant and two Lamivudine-susceptive DHBV complete genomes were successfully amplified, sequenced and then submitted to GenBank. All the DHBV complete sequences in the GenBank at present were taken to align with the three LRDHBV to analyze the mutational points related to the Lamivudine-resistant mutation.

RESULTS

Both the animal and cell model showed that the large and the small dosage Lamivudine have no significant inhibitory effect on the LRDHBV. Five sequences of DHBV complete genomes were successfully cloned. The GenBank accession numbers of the three sequences of LRDHBV are AY521226, AY521227, and AY433937. The two strains of Lamivudine-susceptive DHBV are AY392760 and AY536371. The correlated mutational points are KorR86Q and AorE591T in the P protein.

CONCLUSION

The Lamivudine resistance character of this DHBV strain is caused by genome mutation; the related mutational points are KorR86Q and AorE591T and have no relations with the YMDD motif mutation.

摘要

目的

观察一株鸭乙肝病毒(DHBV)体外及体内对拉米夫定的耐药特性,并分析其耐药特性是由基因突变还是拉米夫定代谢异常所致。

方法

以先天性DHBV阴性的广东麻鸭和鸭胚肝细胞分别作为动物和细胞模型。感染对拉米夫定敏感的DHBV和对拉米夫定耐药的DHBV(LRDHBV),并按分组给予拉米夫定。检测动物和细胞模型中DHBV数量的变化。成功扩增、测序3株对拉米夫定耐药和2株对拉米夫定敏感的DHBV全基因组,然后提交至GenBank。将GenBank中目前所有的DHBV全序列与3株LRDHBV进行比对,分析与拉米夫定耐药突变相关的突变位点。

结果

动物和细胞模型均显示,大剂量和小剂量拉米夫定对LRDHBV均无显著抑制作用。成功克隆了5个DHBV全基因组序列。3株LRDHBV序列的GenBank登录号分别为AY521226、AY521227和AY433937。2株对拉米夫定敏感的DHBV分别为AY392760和AY536371。相关突变位点为P蛋白中的KorR86Q和AorE591T。

结论

该DHBV株的拉米夫定耐药特性是由基因组突变引起的;相关突变位点为KorR86Q和AorE591T,与YMDD基序突变无关。

相似文献

1
Mutations outside the YMDD motif in the P protein can also cause DHBV resistant to Lamivudine.P蛋白中YMDD基序之外的突变也可导致鸭乙肝病毒对拉米夫定耐药。
World J Gastroenterol. 2005 Jul 21;11(27):4261-7. doi: 10.3748/wjg.v11.i27.4261.
2
Hepatitis B virus (HBV) genotype and YMDD motif mutation profile among patients infected with HBV and untreated with lamivudine.未接受拉米夫定治疗的乙肝病毒(HBV)感染者的HBV基因型及YMDD基序突变情况
Int J Infect Dis. 2008 Jan;12(1):83-7. doi: 10.1016/j.ijid.2007.05.001. Epub 2007 Aug 14.
3
In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.2',3'-二脱氧-3'-氟鸟苷抗乙型肝炎病毒活性及交叉耐药谱的体外特性研究
Antimicrob Agents Chemother. 2006 Mar;50(3):955-61. doi: 10.1128/AAC.50.3.955-961.2006.
4
Identification of rare polymerase variants of hepatitis B virus using a two-stage PCR with peptide nucleic acid clamping.使用肽核酸钳夹的两阶段聚合酶链反应鉴定乙型肝炎病毒的罕见聚合酶变体
J Med Virol. 2004 Apr;72(4):558-65. doi: 10.1002/jmv.20026.
5
YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine.慢性乙型肝炎患者治疗前的YMDD突变体并非由拉米夫定选择产生。
J Med Virol. 2004 Oct;74(2):361-6. doi: 10.1002/jmv.20185.
6
Mutational patterns of hepatitis B virus genome and clinical outcomes after emergence of drug-resistant variants during lamivudine therapy: analyses of the polymerase gene and full-length sequences.拉米夫定治疗期间耐药变异株出现后乙型肝炎病毒基因组的突变模式及临床结局:聚合酶基因和全长序列分析
J Med Virol. 2007 Nov;79(11):1664-70. doi: 10.1002/jmv.20984.
7
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy.长期拉米夫定治疗期间YMDD基序突变型乙型肝炎病毒的出现与取代以及治疗停止后野生型病毒的重新取代
Hepatology. 1998 Jun;27(6):1711-6. doi: 10.1002/hep.510270634.
8
Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.慢性乙型肝炎患者拉米夫定耐药的临床和病毒学特征:单中心经验
J Med Virol. 2005 Mar;75(3):391-8. doi: 10.1002/jmv.20281.
9
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.在未接受过治疗的乙型肝炎病毒(HBV)感染患者中,无论是否合并感染HIV,与拉米夫定耐药相关的突变:对南非HBV和HIV合并感染患者抗逆转录病毒治疗的影响
J Med Virol. 2007 Nov;79(11):1650-4. doi: 10.1002/jmv.20974.
10
Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
Intervirology. 2006;49(5):274-80. doi: 10.1159/000093457. Epub 2006 May 22.

本文引用的文献

1
Four years of treatment with lamivudine: clinical and virological evaluations in HBe antigen-negative chronic hepatitis B.拉米夫定四年治疗:HBe抗原阴性慢性乙型肝炎的临床和病毒学评估
Aliment Pharmacol Ther. 2004 Aug 1;20(3):281-7. doi: 10.1111/j.1365-2036.2004.02073.x.
2
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.乙型肝炎病毒流行病学、疾病负担、治疗以及当前和新出现的预防控制措施。
J Viral Hepat. 2004 Mar;11(2):97-107. doi: 10.1046/j.1365-2893.2003.00487.x.
3
Hepatitis B.乙型肝炎
Am Fam Physician. 2004 Jan 1;69(1):75-82.
4
[The long-term efficacy of lamivudine in chronic hepatitis B: interim analysis of 3-year's clinical course].[拉米夫定治疗慢性乙型肝炎的长期疗效:3年临床病程的中期分析]
Zhonghua Nei Ke Za Zhi. 2003 Jun;42(6):382-7.
5
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.
Gastroenterology. 2001 Mar;120(4):1000-8. doi: 10.1053/gast.2001.22454.
6
Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.
J Hepatol. 2001 Jan;34(1):114-22. doi: 10.1016/s0168-8278(00)00074-x.
7
[Long-term effect of lamivudine treatment in chronic hepatitis B virus infection].拉米夫定治疗慢性乙型肝炎病毒感染的长期疗效
Zhonghua Gan Zang Bing Za Zhi. 1999 Jun;7(2):80-3.
8
Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.乙型肝炎病毒聚合酶YMDD基序外的其他突变在L(-)SddC(3TC)耐药中的作用
Biochem Pharmacol. 1998 May 15;55(10):1567-72. doi: 10.1016/s0006-2952(98)00050-1.
9
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.对拉米夫定耐药的乙型肝炎病毒突变的鉴定与特征分析。拉米夫定临床研究组。
Hepatology. 1998 Jun;27(6):1670-7. doi: 10.1002/hep.510270628.
10
Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment.在长期拉米夫定治疗期间出现的乙肝病毒聚合酶基因中不止一种突变的鉴定。
J Infect Dis. 1998 May;177(5):1382-5. doi: 10.1086/517819.